HOME- R&D
- Bryn Mawr Conference
- Workshops & Training
- Program
- Drug Discovery Innovation
- Abstracts
- Speakers
- Blank, L
- Boyer, S
- Cook, J
- Gibbs, A
- Hopfgartner, G
- Lett, G.S.
- Lobanov, V
- Mosenkis, D
- Nieuwenhuis, J
- Wikel, J
- Wiseman, J
- Zauhar, R
- Proteins
- Quantum Biochemistry
- Screening
- Web Services
- Pharmacophores
- Graph Mining
- Nanotech
- Membranes & Ion Channels
- Exhibition
- Registration
- Jobs
- Contact
- Schedule
|
|
|
|
|
|
|
| Lars M. Blank, University of Dortmund & the ISAS, Dortmund |
|
Dr. Lars M. Blank, was born 1969 in Hilden, Germany, studied Chemical Engineering (Bioprocess Engineering) from 1990 to 1997 at the University of Dortmund (Germany) and Biology (Microbiology) from 1992 to 1997 at the Ruhr-University of Bochum (Germany) . He did his Master's thesis in the field of Metabolic Engineering in the group of Prof. E.T. Papoutsakis at Northwestern University, IL, USA. He carried out his Ph.D. project "Metabolic Engineering of Lactic Acid Bacteria" at the University of Queensland, Australia (until May 2002). During his Ph.D. he worked as a visiting scientist at the Technical University of Denmark (DtU), Lyngby, Denmark (Sept. - Dec. 1999). As a postdoctoral fellow of the Deutsche Akademie der Naturforscher Leopoldina (Halle, Germany) he established flux analysis as an additional tool for yeast Systems Biology in the group of Prof. U. Sauer at the ETH Zurich, Switzerland. Since November 2004 he has lead the Systems Biotechnology group as the chair of Chemical Biotechnology at the University of Dortmund and is a senior research fellow at the Institute for Analytical Sciences (ISAS) in Dortmund, an Institute of the Leibniz Gemeinschaft. Dr. Blank focuses in his research on fundamental and applied aspects of microbial metabolism. Of specific interest are quantitative tools for the description of the capacity of microbial metabolism under production conditions. Such research on in silico/in vivo flux and metabolome analyses will allow the improvement of production strains for fine chemicals that are relevant for the pharma industry.
|
| |
|
|
|
|
|
|
|
|